S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?

29/12/2023 25 min Temporada 19 Episodio 1
S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?

Listen "S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?"

Episode Synopsis

In this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinicians should have HER3 on their radar.
Visit www.morningcommutepodcast.com/HER3Agnostic1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

More episodes of the podcast Hematology / Oncology @Point of Care Podcasts